Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Named Ion Torrent CSP

NEW YORK (GenomeWeb News) – Asuragen today said that it has been named a certified service provider for Ion Torrent's Personal Genome Machine.

Austin, Texas-based Asuragen will use the Ion Torrent platform to provide targeted DNA mutation analysis of tumor samples to identify known and de novo mutations within FFPE and FNA specimens. The services will include both Asuragen's SuraSeq custom cancer panels and the Ion AmpliSeq cancer panel.

The CSP program is designed to assure customers that Asuragen has been trained and tested by Life Technologies' Ion Torrent business in the use of the semiconductor-based sequencing technology.

"The PGM next-generation sequencing allows us to expand our proven platform of molecular sample interrogation to assist our customers in their targeted drug and diagnostic development programs," Carol Berry, SVP and GM of Asuragen's Pharmacogenomic Services Division, said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.